Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug “Improvements” May Be Undercut By New Market Share Fees

Executive Summary

The Treasury Department’s plans for implementing the branded drug market share fee program mandated by the Affordable Care Act have raised concerns that investment in orphan drug development could be discouraged by a “narrow” reading of the law.

You may also be interested in...



Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees

Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.

Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees

Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.

Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says

The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.

Related Content

Topics

UsernamePublicRestriction

Register

PS052836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel